New Delhi, Nov 14 (PTI) Biocon's contract research armSyngene International has expanded its ongoing drug discoveryand development with US-based Bristol-Myers Squibb till 2026.
The company today said the expanded scope of partnershipalso includes addition of a new facility and ramping up theteam of scientists working for it.
"The next phase of the partnership will see the additionof a new facility to support future Bristol-Myers Squibbresearch and development operations, an expansion of the teamand the extension of the existing agreement through 2026,"Syngene International said in a BSE filing.
"The expansion will enable the two companies to undertakea greater range of scientific research and development forpharmaceuticals across a broader range of activities," itadded.
As part of the expansion, Syngene will set up a newdedicated facility spread across 25,000 sq ft of laboratoryand office space for Bristol-Myers Squibb.
This facility will house an additional team of 75 Syngenescientists who will work exclusively for Bristol-Myers Squibb.
Syngene and Bristol-Myers Squibb have been workingtogether since 1998. The research campus, known as Biocon BMSResearch Center (BBRC), Syngene's first dedicated R&D centre,was established in 2007, which was subsequently renewedthrough 2020 and now has been extended through 2026.
It is the largest research and development facility forBristol-Myers Squibb outside the United States and plays anintegral part within their global research and developmentnetwork, Syngene said. PTI SVKARD.
This is unedited, unformatted feed from the Press Trust of India wire.